Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UT Southwestern Medical Center

Sites in Dallas, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1262
Shown on this page
12
Current sort
Recently updated
Campus scope
UT Southwestern Medical Center, Dallas, TX
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UT Southwestern Medical Center, Dallas, TX. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 637–648 of 1,262 matching trials with a site at UT Southwestern Medical Center, Dallas, TX.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

NCT04134260
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Hormone Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
348
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 259 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Phase 3 Interventional

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

NCT04865939
Status at this site: Recruiting
View directory record Official record
Conditions
Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Ureter
Interventions
sterile water irrigation, Gemcitabine
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting No phase listed Observational

TRACK-TBI Longitudinal Biomarker Study

NCT05201833
Site status not listed — check the official record
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Telephone Outcome Assessment, In-Person Outcome Assessment, 3T Magnetic Resonance Imaging (MRI), Blood Draw
Behavioral · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
San Francisco, California • Charlestown, Massachusetts • Cincinnati, Ohio + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting Not applicable Interventional

XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)

NCT05881278
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Failure, Transplant; Failure, Heart
Interventions
Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
Device
Lead sponsor
XVIVO Perfusion
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Not yet recruiting Not applicable Interventional

Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)

NCT07756398
Site status not listed — check the official record
View directory record Official record
Conditions
Valvular Heart Disease Patients, Aortic Stenosis, Mitral Regurgitation, Left Ventricular Diastolic Dysfunction
Interventions
Kosmos Torso-One AI-guided Point-of-Care Ultrasound (EchoNous, Inc.)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years to 85 Years
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Phase 2 Interventional

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
FG-3246
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Not applicable Interventional

Alleviant ALLAY-HF Study

NCT05685303
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Failure
Interventions
Alleviant ALV1 System, Sham-Control
Device · Other
Lead sponsor
Alleviant Medical, Inc.
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
56
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
15
States / cities
Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Phase 3 Interventional

Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

NCT07623668
Status at this site: Recruiting
View directory record Official record
Conditions
Optic Neuritis
Interventions
Privosegtor, Methylprednisolone, Placebo
Drug · Other
Lead sponsor
Oculis
Industry
Eligibility
18 Years to 50 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Livonia, Michigan • Charleston, South Carolina • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

NCT07196644
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumors Harboring MET Amplification
Interventions
Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Phase 4 Interventional

Once Weekly Infant Corticosteroid Trial for DMD

NCT05412394
Status at this site: Recruiting
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Prednisolone
Drug
Lead sponsor
Anne M. Connolly
Other
Eligibility
1 Month to 30 Months · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

NCT05211323
Site status not listed — check the official record
View directory record Official record
Conditions
Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Cisplatin, Computed Tomography, Conventional Magnetic Resonance Imaging, Gemcitabine Hydrochloride
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Auburn, California • Berkeley, California • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 31, 2026, 1:49 PM EDT

About this UT Southwestern Medical Center institution page

What this page lists
ClinicalTrials.gov records that list UT Southwestern Medical Center in Dallas, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.